Increases in seizure latencies induced by subcutaneous docosahexaenoic acid are lost at higher doses

Epilepsy Research

Volumn 99, Issue 3, 2012, Pages 225-232

  Trépanier, Marc Olivier ^a   Taha, Ameer Y ^a   Mantha, Rebecca L ^a   Ciobanu, Flaviu A ^a   Zeng, Qiudi H ^a   Tchkhartichvili, George M ^a   Domenichiello, Anthony F ^a   Bazinet, Richard P ^a   Burnham, W M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Docosahexaenoic acid; Dose response; Epilepsy; Fatty acid release; PTZ; Seizures

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; OLEIC ACID; PENTETRAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; FATTY ACID ANALYSIS; FATTY ACID SYNTHESIS; LATENT PERIOD; LIPID BRAIN LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE THRESHOLD; TONIC CLONIC SEIZURE;

ANIMALS; ANTICONVULSANTS; DOCOSAHEXAENOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; RANDOM ALLOCATION; RATS; RATS, WISTAR; SEIZURES; TIME FACTORS;

EID: 84860435940     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2011.12.001     Document Type: Article

References (36)

1. Amminger G.P., Schafer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiat. 2010, 67:146-154.
2. Bazan N.G., Aveldano de Caldironi M.I., Rodriguez de Turco E.B. Rapid release of free arachidonic acid in the central nervous system due to stimulation. Prog. Lipid Res. 1981, 20:523-529.
3. Bazan N.G. Changes in free fatty acids of brain by drug-induced convulsions, electroshock and anaesthesia. J. Neurochem. 1971, 18:1379-1385.
4. Bazan N.G. Effects of ischemia and electroconvulsive shock on free fatty acid pool in the brain. Biochim. Biophys. Acta 1970, 218:1-10.
5. Bazan N.G. Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. Curr. Opin. Clin. Nutr. Metab. Care 2007, 10:136-141.
6. Bazan N.G., Molina M.F., Gordon W.C. Docosahexaenoic Acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. Annu. Rev. Nutr. 2011, 31:321-351.
7. Burnham W.M. Antiseizure drugs. Principles of Medical Pharmacology 2007, 223-235. Saunders, Toronto. 7th ed. H. Kalant, D.M. Grant, J. Mitchell (Eds.).
8. Cao D., Kevala K., Kim J., Moon H.S., Jun S.B., Lovinger D., Kim H.Y. Docosahexaenoic acid promotes hippocampal neuronal development and synaptic function. J. Neurochem. 2009, 111:510-521.
9. Chen C.T., Ma D.W., Kim J.H., Mount H.T., Bazinet R.P. The low density lipoprotein receptor is not necessary for maintaining mouse brain polyunsaturated fatty acid concentrations. J. Lipid Res. 2008, 49:147-152.
10. Cunnane S.C., Musa K., Ryan M.A., Whiting S., Fraser D.D. Potential role of polyunsaturates in seizure protection achieved with the ketogenic diet. Prostaglandins Leukot. Essent Fatty Acids 2002, 67:131-135.
11. Farias S.E., Basselin M., Chang L., Heidenreich K.A., Rapoport S.I., Murphy R.C. Formation of eicosanoids, E2/D2 isoprostanes, and docosanoids following decapitation-induced ischemia, measured in high-energy-microwaved rat brain. J. Lipid Res. 2008, 49:1990-2000.
12. Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 1957, 226:497-509.
13. Green J.T., Orr S.K., Bazinet R.P. The emerging role of group VI calcium-independent phospholipase A2 in releasing docosahexaenoic acid from brain phospholipids. J. Lipid Res. 2008, 49:939-944.
14. Guberman A., Bruni J. Essentials of Clinical Epilepsy 1999, Butterworth-Heinemann, Woburn. 2nd ed.
15. Hamilton J.A., Johnson R.A., Corkey B., Kamp F. Fatty acid transport: the diffusion mechanism in model and biological membranes. J. Mol. Neurosci. 2001, 16:99-108. discussion 151-107.
16. + channels by directly binding to the channel proteins. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:3542-3546.
17. Kubova H., Mares P. Anticonvulsant effects of phenobarbital and primidone during ontogenesis in rats. Epilepsy Res. 1991, 10:148-155.
18. McNamara J.O., Rigsbee L.C., Butler L.S., Shin C. Intravenous phenytoin is an effective anticonvulsant in the kindling model. Ann. Neurol. 1989, 26:675-678.
19. Musto A.E., Gjorstrup P., Bazan N.G. The omega-3 fatty acid-derived neuroprotectin D1 limits hippocampal hyperexcitability and seizure susceptibility in kindling epileptogenesis. Epilepsia 2011.
20. Orr S.K., Bazinet R.P. The emerging role of docosahexaenoic acid in neuroinflammation. Curr. Opin. Investig. Drugs 2008, 9:735-743.
21. Ouellet M., Emond V., Chen C.T., Julien C., Bourasset F., Oddo S., LaFerla F., Bazinet R.P., Calon F. Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: an in situ cerebral perfusion study. Neurochem. Int. 2009, 55:476-482.
22. Peet M., Horrobin D.F. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch. Gen. Psychiat. 2002, 59:913-919.
23. Serrano E.E., Wilder B.J. Intramuscular administration of diphenylhydantoin. Histologic follow-up studies. Arch. Neurol. 1974, 31:276-278.
24. Serhan C.N., Yacoubian S., Yang R. Anti-inflammatory and proresolving lipid mediators. Annu. Rev. Pathol. 2008, 3:279-312.
25. Song B.J., Elbert A., Rahman T., Orr S.K., Chen C.T., Febbraio M., Bazinet R.P. Genetic ablation of CD36 does not alter mouse brain polyunsaturated fatty acid concentrations. Lipids 2010, 45:291-299.
26. Stoll A.L., Severus W.E., Freeman M.P., Rueter S., Zboyan H.A., Diamond E., Cress K.K., Marangell L.B. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch. Gen. Psychiat. 1999, 56:407-412.
27. Taha A.Y., Jeffrey M.A., Taha N.M.Y., Bala S., Burnham W.M. Acute administration of docosahexaenoic acid increases resistance to pentylenetetrazol-induced seizures in rats. Epilepsy Behav. 2010, Epub.
28. Tavazzi L., Maggioni A.P., Marchioli R., Barlera S., Franzosi M.G., Latini R., Lucci D., Nicolosi G.L., Porcu M., Tognoni G. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1223-1230.
29. Vilesek L. Models of chemically-induced acute seizures. Models of Seizures and Epilepsy 2006, 127-152. Academic Press, Burlington, MA. 1st ed. A. Pitkanen, P.A. Schwartzkroin, S.L. Moshe (Eds.).
30. Voskuyl R.A., Vreugdenhil M., Kang J.X., Leaf A. Anticonvulsant effect of polyunsaturated fatty acids in rats, using the cortical stimulation model. Eur. J. Pharmacol. 1998, 341:145-152.
31. Vreugdenhil M., Bruehl C., Voskuyl R.A., Kang J.X., Leaf A., Wadman W.J. Polyunsaturated fatty acids modulate sodium and calcium currents in CA1 neurons. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:12559-12563.
32. Xiao Y.F., Kang J.X., Morgan J.P., Leaf A. Blocking effects of polyunsaturated fatty acids on Na+channels of neonatal rat ventricular myocytes. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:11000-11004.
33. Xiao Y.F., Li X. Polyunsaturated fatty acids modify mouse hippocampal neuronal excitability during excitotoxic or convulsant stimulation. Brain Res. 1999, 846:112-121.
34. Yavin E. Versatile roles of docosahexaenoic acid in the prenatal brain: from pro- and anti-oxidant features to regulation of gene expression. Prostaglandins Leukot. Essent Fatty Acids 2006, 75(3):203-211.
35. Young C., Gean P.W., Chiou L.C., Shen Y.Z. Docosahexaenoic acid inhibits synaptic transmission and epileptiform activity in the rat hippocampus. Synapse 2000, 37:90-94.
36. Yuen A.W., Sander J.W. Is omega-3 fatty acid deficiency a factor contributing to refractory seizures and SUDEP? A hypothesis. Seizure 2004, 13:104-107.